[Alternating hemiplegia with epilepsy]

N V Chebanenko1, V P Zykov1, I B Komarova1

  • 1Russian Medical Academy of Continuous Professional Education, Moscow, Russia.

Insights

A child with alternating hemiplegia and epilepsy had seizures diagnosed using video-EEG monitoring. Genetic testing identified an ATP1A3 gene mutation, leading to targeted therapy that successfully stopped both seizure types.

Area of Science:

  • Neurology
  • Genetics
  • Epileptology

Background:

  • Alternating hemiplegia of childhood (AHC) is a rare neurological disorder characterized by recurrent episodes of unilateral motor impairment.
  • Epilepsy is a common neurological condition involving recurrent seizures, which can sometimes complicate the diagnosis of other disorders.
  • The co-occurrence of AHC and epilepsy presents diagnostic challenges due to overlapping or distinct seizure manifestations.

Observation:

  • A pediatric case presented with complex seizure activity, initially hindering a definitive diagnosis.
  • Video-electroencephalography (EEG) monitoring was crucial in differentiating between epileptic and non-epileptic seizures occurring concurrently with different patterns.
  • Simultaneous epileptic and non-epileptic seizures were identified, complicating the clinical picture.

Findings:

  • Genetic analysis, including genome-wide sequencing, confirmed a mutation in the ATP1A3 gene, the known cause of AHC.
  • The identified ATP1A3 gene mutation provided a definitive genetic diagnosis for the patient's condition.
  • Timely initiation of targeted therapy based on the genetic diagnosis was achieved.

Implications:

  • This case highlights the importance of advanced diagnostic tools like video-EEG and genetic sequencing in complex neurological cases.
  • Targeted therapy directed at the underlying genetic defect (ATP1A3 mutation) proved effective in managing both epileptic and non-epileptic seizures.
  • Successful treatment demonstrates the potential for precision medicine in managing rare genetic neurological disorders like AHC with co-existing epilepsy.

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
889
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
781
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
652
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
901
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
574